Viking Therapeutics VKTX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -70%-22.7pp | -47.3%-18.1pp | -29.2%-9.2pp | -20%-5.6pp | -14.4%+3.5pp | |
| Return on assets | -64%-19.7pp | -44.3%-16.0pp | -28.3%-9.0pp | -19.3%-5.4pp | -14%+3.2pp | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | 0×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 5.7×-3.6× | 9.3×-19.0× | 28.3×+2.5× | 25.9×-18.4× | 44.2×+11.2× | |
| Quick ratio | 5.7×-3.6× | 9.3×-19.0× | 28.3×+2.5× | 25.9×-18.4× | 44.2×+11.2× | |
| Cash ratio | 1.1×-1.1× | 2.2×-1.7× | 3.9×+2.8× | 1.1×-0.9× | 1.9×+1.0× | |
| Leverage | ||||||
| Interest coverage | -16.9×-5.3× | -11.7×-4.3× | -7.3×-2.2× | -5.2×-1.2× | -3.9×-0.2× | |
| Per Share | ||||||
| Book value per share | $4.34-23.4% | $5.67-10.7% | $6.35-10.5% | $7.09-6.1% | $7.56-6.4% | |
| Valuation | ||||||
| Market capitalization | $3.76B-5.4% | $3.98B+34.6% | $2.96B-2.4% | $3.03B+11.7% | $2.71B-39.5% | |
| Price / book | 7.5×+1.3× | 6.2×+2.1× | 4.1×+0.3× | 3.8×+0.6× | 3.2×-1.9× | |
| Earnings yield | -12.6%-3.5pp | -9%-1.0pp | -8%-2.4pp | -5.7%-0.9pp | -4.7%-2.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Viking Therapeutics's ratios come from?
- Every ratio is computed from Viking Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.